Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cancer continues to be a leading threat to human health and life. Resistance to anti-cancer
drugs is a major impediment towards efficacious cancer treatment. p53 mutations play an …
drugs is a major impediment towards efficacious cancer treatment. p53 mutations play an …
Current insights into epigenetics, noncoding RNA interactome and clinical pharmacokinetics of dietary polyphenols in cancer chemoprevention
Several studies have reported the health-beneficial effects of dietary phytochemicals,
namely polyphenols, to prevent various diseases, including cancer. Polyphenols, like (−) …
namely polyphenols, to prevent various diseases, including cancer. Polyphenols, like (−) …
Therapeutic role of curcumin and its novel formulations in gynecological cancers
MH Pourhanifeh, M Darvish, J Tabatabaeian… - Journal of Ovarian …, 2020 - Springer
Gynecological cancers are among the leading causes of cancer-associated mortality
worldwide. While the number of cases are rising, current therapeutic approaches are not …
worldwide. While the number of cases are rising, current therapeutic approaches are not …
Curcumin and cancer; are long non-coding RNAs missing link?
AG Shabgah, SH Zarifi, SSM Kiapey, F Ezzatifar… - Progress in biophysics …, 2021 - Elsevier
Despite significant signs of progress in cancer treatment over the past decade, either cancer
prevalence or mortality continuously grow worldwide. Current anti-cancer agents show …
prevalence or mortality continuously grow worldwide. Current anti-cancer agents show …
Metallothionein isoforms as double agents–their roles in carcinogenesis, cancer progression and chemoresistance
MAM Rodrigo, AMJ Jimemez, Y Haddad… - Drug Resistance …, 2020 - Elsevier
Metallothioneins (MTs) are small cysteine-rich intracellular proteins with four major isoforms
identified in mammals, designated MT-1 through MT-4. The best known biological functions …
identified in mammals, designated MT-1 through MT-4. The best known biological functions …
Functional interplay between long non-coding RNAs and Breast CSCs
Breast cancer (BC) represents aggressive cancer affecting most women's lives globally.
Metastasis and recurrence are the two most common factors in a breast cancer patient's …
Metastasis and recurrence are the two most common factors in a breast cancer patient's …
[HTML][HTML] A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer
Y Xie, Z Ren, H Chen, H Tang, M Zhu, Z Lv… - Biomedicine & …, 2023 - Elsevier
Ovarian cancer is the second cause of death among gynecological malignancies. In this
study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin …
study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin …
A novel targeted therapy system for cervical cancer: co-delivery system of antisense LncRNA of MDC1 and oxaliplatin magnetic thermosensitive cationic liposome …
H Ye, X Chu, Z Cao, X Hu, Z Wang, M Li… - International Journal …, 2021 - Taylor & Francis
Background This study was aimed to prepare a novel magnetic thermosensitive cationic
liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 …
liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 …
Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs
E Seyed Hosseini, M Alizadeh Zarei… - Biological Research, 2023 - Springer
Background Contrary to the advantageous anticancer activities of curcumin (Cur), limited
bioavailability and solubility hindered its efficacy. Here, nontoxic dendrosomal nano carrier …
bioavailability and solubility hindered its efficacy. Here, nontoxic dendrosomal nano carrier …
Polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer
SL Levit, C Tang - Nanomaterials, 2021 - mdpi.com
Treatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug
resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination …
resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination …